Prevenar 13 + Pneumovax 23

Prevenar 13 + Pneumovax 23 refers to a sequential prime-boost vaccination strategy being evaluated by University Hospital, Tours, in the EVAPOR clinical trial (NCT04214444). This regimen involves the initial administration of Prevenar 13 (a 13-valent pneumococcal conjugate vaccine, PCV13) followed by a booster dose of Pneumovax 23 (a 23-valent pneumococcal polysaccharide vaccine, PPV23) at least two months later. The strategy is specifically designed to optimize the immune response in immunocompromised patients, such as those with diffuse large B-cell lymphoma (DLBCL) receiving rituximab-based immunochemotherapy. Prevenar 13 utilizes a conjugate platform to induce T-cell-dependent immune responses and memory B-cell formation, while Pneumovax 23 provides broader coverage against 23 Streptococcus pneumoniae serotypes through a polysaccharide-based platform. The goal of this sequential approach is to provide both long-term immunological memory and broad protection against invasive pneumococcal disease.

Brand names

Prevenar 13Prevenar13Prevenar-13Pneumovax 23Pneumovax23Pneumovax-23

Other names

anti-pneumococcal vaccine-University Hospital, Tours-pneumococcal infectionPCV13 + PPV23 prime-boost strategyEVAPOR study vaccine strategy